Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Immunotherapy in pituitary carcinomas and aggressive pituitary tumors.

Best practice & research. Clinical endocrinology & metabolism - 1 Dec 2022

Raverot Gérald, Ilie Mirela Diana

Abstract excerpt

After temozolomide failure, no evidence-based treatment option is currently available for aggressive pituitary tumors (APTs) and pituitary carcinomas (PCs). Moreover, once temozolomide has failed, the survival of these patients is very poor. The use of immune-checkpoint inhibitors (ICIs) has been so far reported in a large cohort, a small phase 2 clinical trial, and in another five isolated cases (24 cases in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Immunotherapy
Share to Microsatellite Instability

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Pituitary Neoplasms

Share to Temozolomide

Source

Identifiers

PMID: 36274025
DOI: 10.1016/j.beem.2022.101712

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Immunotherapy in pituitary carcinomas and aggressive pituitary tumors.PMID 36274025Read ↗

Predictive Capacity of Mismatch Repair Status in the Use of Immune Checkpoint Inhibitors for the Treatment of Aggressive Pituitary Adenomas and Pituitary Carcinomas: Illustrative Case Report and Literature ReviewSemantic proximity Read ↗

Aggressive Pituitary TumorsSemantic proximity Read ↗

From Genes to Therapy: Pituitary Adenomas in the Era of Precision MedicineSemantic proximity Read ↗

The role of temozolomide in the treatment of aggressive pituitary tumors.Semantic proximity Read ↗

Genome-wide loss of heterozygosity predicts aggressive, treatment-refractory behavior in pituitary neuroendocrine tumors.Semantic proximity Read ↗

Tumor Immune Microenvironment in Pituitary Neuroendocrine Tumors (PitNETs): Increased M2 Macrophage Infiltration and PD-L1 Expression in PIT1-lineage SubsetSemantic proximity Read ↗

The hallmarks of cancer… in pituitary tumors?Semantic proximity Read ↗

MiRNAs as Noninvasive Biomarkers and Therapeutic Agents of Pituitary AdenomasSemantic proximity Read ↗

Marked Response of a Hypermutated ACTH-Secreting Pituitary Carcinoma to Ipilimumab and Nivolumab.Semantic proximity Read ↗

Single-cell transcriptomic analysis reveals tumor cell heterogeneity and immune microenvironment features of pituitary neuroendocrine tumorsSemantic proximity Read ↗

A review of multiomics platforms in pituitary adenoma pathogenesisSemantic proximity Read ↗

Transcription Factor–Based Classification of Pituitary Neuroendocrine Tumors: Practical Immunohistochemical Algorithms, Molecular Correlates, and Diagnostic Challenges in the 5th WHO EraSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.